SG11202003677UA - Compounds useful for inhibiting cdk7 - Google Patents

Compounds useful for inhibiting cdk7

Info

Publication number
SG11202003677UA
SG11202003677UA SG11202003677UA SG11202003677UA SG11202003677UA SG 11202003677U A SG11202003677U A SG 11202003677UA SG 11202003677U A SG11202003677U A SG 11202003677UA SG 11202003677U A SG11202003677U A SG 11202003677UA SG 11202003677U A SG11202003677U A SG 11202003677UA
Authority
SG
Singapore
Prior art keywords
compounds useful
inhibiting cdk7
cdk7
inhibiting
compounds
Prior art date
Application number
SG11202003677UA
Other languages
English (en)
Inventor
David Andrew Coates
Carlos Montero
Bharvin Kumar Rameschandra Patel
David Michael Remick
Vipin Yadav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202003677UA publication Critical patent/SG11202003677UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202003677UA 2017-11-16 2018-11-09 Compounds useful for inhibiting cdk7 SG11202003677UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
EP18382034 2018-01-23
EP18382546 2018-07-20
PCT/US2018/060025 WO2019099298A1 (en) 2017-11-16 2018-11-09 Compounds useful for inhibiting cdk7

Publications (1)

Publication Number Publication Date
SG11202003677UA true SG11202003677UA (en) 2020-05-28

Family

ID=64477309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003677UA SG11202003677UA (en) 2017-11-16 2018-11-09 Compounds useful for inhibiting cdk7

Country Status (31)

Country Link
US (3) US10472370B2 (ar)
EP (1) EP3710446B1 (ar)
JP (1) JP6633254B2 (ar)
KR (1) KR102450727B1 (ar)
CN (1) CN111344292B (ar)
AU (1) AU2018369508B2 (ar)
BR (1) BR112020008253A2 (ar)
CA (1) CA3080910C (ar)
CL (1) CL2020001218A1 (ar)
CR (1) CR20200184A (ar)
DK (1) DK3710446T3 (ar)
DO (1) DOP2020000102A (ar)
EC (1) ECSP20025899A (ar)
ES (1) ES2925219T3 (ar)
HR (1) HRP20221152T1 (ar)
HU (1) HUE060078T2 (ar)
IL (1) IL274540B (ar)
JO (1) JOP20200122B1 (ar)
LT (1) LT3710446T (ar)
MD (1) MD3710446T2 (ar)
MX (1) MX2020004932A (ar)
MY (1) MY197700A (ar)
NZ (1) NZ763551A (ar)
PE (1) PE20210392A1 (ar)
PL (1) PL3710446T3 (ar)
RS (1) RS63530B1 (ar)
SA (1) SA520411990B1 (ar)
SG (1) SG11202003677UA (ar)
SI (1) SI3710446T1 (ar)
TW (1) TWI703149B (ar)
WO (1) WO2019099298A1 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129371B1 (en) * 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
CN114901284A (zh) * 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
AU2020404326A1 (en) 2019-12-20 2022-08-11 Evopoint Biosciences Co., Ltd. Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof
WO2022033552A1 (zh) * 2020-08-12 2022-02-17 隆泰申医药科技(南京) 有限公司 Cdk激酶抑制剂、其制备方法、药物组合物和应用
USD1004119S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD1004118S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD987844S1 (en) 2021-08-31 2023-05-30 MerchSource, LLC Percussion massager
USD1004117S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD994898S1 (en) 2021-11-17 2023-08-08 MerchSource, LLC Percussion massager
USD995812S1 (en) 2021-11-22 2023-08-15 MerchSource, LLC Percussion massager
USD1009292S1 (en) 2021-12-22 2023-12-26 MerchSource, LLC Percussion massager
USD1018881S1 (en) 2021-12-22 2024-03-19 MerchSource, LLC Percussion massager
USD1004122S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
USD1004121S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
WO2024125532A1 (zh) * 2022-12-12 2024-06-20 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298571B2 (en) * 2002-09-04 2006-10-19 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3129371B1 (en) * 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978170C (en) * 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CN107427521B (zh) * 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
LT3302448T (lt) 2015-06-04 2024-02-12 Aurigene Oncology Limited Pakeisti heterociklilo dariniai kaip cdk inhibitoriai
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物

Also Published As

Publication number Publication date
SI3710446T1 (sl) 2022-09-30
JP2019537616A (ja) 2019-12-26
US20200017513A1 (en) 2020-01-16
RS63530B1 (sr) 2022-09-30
LT3710446T (lt) 2022-09-26
US20210032257A1 (en) 2021-02-04
AU2018369508B2 (en) 2021-03-11
ES2925219T3 (es) 2022-10-14
MD3710446T2 (ro) 2022-12-31
CN111344292A (zh) 2020-06-26
HRP20221152T1 (hr) 2022-11-25
SA520411990B1 (ar) 2022-07-24
KR20200070323A (ko) 2020-06-17
JOP20200122B1 (ar) 2023-09-17
CN111344292B (zh) 2022-06-03
TW201930305A (zh) 2019-08-01
CR20200184A (es) 2020-06-01
PE20210392A1 (es) 2021-03-02
BR112020008253A2 (pt) 2020-11-17
US20190144456A1 (en) 2019-05-16
IL274540A (en) 2020-06-30
IL274540B (en) 2022-06-01
EP3710446A1 (en) 2020-09-23
ECSP20025899A (es) 2020-06-30
HUE060078T2 (hu) 2023-01-28
WO2019099298A1 (en) 2019-05-23
DOP2020000102A (es) 2020-08-31
DK3710446T3 (da) 2022-08-01
KR102450727B1 (ko) 2022-10-06
NZ763551A (en) 2021-12-24
US10472370B2 (en) 2019-11-12
JOP20200122A1 (ar) 2020-05-20
CA3080910A1 (en) 2019-05-23
CA3080910C (en) 2023-02-07
JP6633254B2 (ja) 2020-01-22
MY197700A (en) 2023-07-06
TWI703149B (zh) 2020-09-01
US10787460B2 (en) 2020-09-29
EP3710446B1 (en) 2022-07-20
CL2020001218A1 (es) 2020-08-21
AU2018369508A1 (en) 2020-05-07
PL3710446T3 (pl) 2022-10-10
MX2020004932A (es) 2020-08-27

Similar Documents

Publication Publication Date Title
IL274540B (en) Compounds useful for cdk7 inhibition
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
SI3589637T1 (sl) Spojine uporabne pri inhibiciji ROR-GAMMA-T
SI3589638T1 (sl) Spojine uporabne pri inhibiciji ROR-GAMMA-T
PT3710446T (pt) Compostos úteis para inibir cdk7
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors